SecBot SecBot
6-K ·Filed Nov 9, 2026

NVO

NOVO NORDISK A S
NEUTRAL
Impact 2/10
Horizonimmediate Processed7d 18h ago SEC0001171843-26-007260
Notable filing: 6-K
Actionable Insight • Neutral

This is a routine weekly update on the ongoing buyback program. No new information on the pace or scope of the program. Monitor for any changes to the buyback authorization or completion announcement.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$41.38
T+0 close · Nov 9, 2026 · via day close
Latest settled
+0.53%
T+5 · $41.60
Vs SPY
+2.22%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $41.38entry
  2. T+1 · 7d ago −1.64%α −1.28% · $40.70
  3. T+5 · 20h ago +0.53%α +2.22% · $41.60
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Novo Nordisk filed a routine 6-K updating its ongoing share repurchase program, reporting the repurchase of 890,000 B shares for approximately DKK 243.6 million between November 3-6, 2026. The filing contains no financial results or material corporate events.

Key Facts

  • Novo Nordisk repurchased 890,000 B shares from November 3-6, 2026 at an average price of DKK 273.57 per share, totaling approximately DKK 243.6 million
  • Total accumulated repurchases under the program initiated May 6, 2026: 27,845,000 B shares for DKK 8.008 billion
  • Overall 12-month buyback program of up to DKK 15 billion began February 4, 2026; as of November 6, 2026, total repurchases were DKK 11.808 billion
  • Company holds 56,644,876 B shares as treasury shares, representing 1.3% of total share capital of 4.465 billion shares

Financial Impact

Routine buyback update; total program size up to DKK 15 billion (~$2.1B at current rates), with DKK 11.8 billion already deployed

share counttreasury shares

Risk Factors

  • No material risks identified in this routine filing

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
28% bullish (36 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-007260
Document: 0001171843-26-007260-index-headers.html0001171843-26-007260
Document: 0001171843-26-007260-index.html0001171843-26-007260
Document: 0001171843-26-007260.txt0001171843-26-007260
Earnings Context (Synthetic; results releases only)0001171843-26-007260

Track record

43 reports on NVO

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +23.56% at T+60 after the Jul 28, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 2/10 Entry $41.89 Now $41.60 −0.69% settles Dec 15
  2. Nov 13, 20264d ago Court Ruling Neutral 3/10 Entry $42.01 Now $41.60 −0.98% settles Dec 15
  3. Nov 13, 20264d ago Court Ruling Neutral 1/10 Entry $42.01 Now $41.60 −0.98% settles Dec 15
  4. Nov 9, 20267d ago 6-K Neutral 2/10 Viewing Entry $41.38 Now $41.60 +0.53% settles Dec 8
  5. Nov 5, 202611d ago Institutional Cluster Neutral 2/10 Entry $40.30 Now $41.60 +3.23% settles Dec 4
  6. Nov 5, 202611d ago 6-K Neutral 2/10 Entry $40.30 Now $41.60 +3.23% settles Dec 4
  7. Nov 4, 202612d ago 6-K Bullish 6/10 Entry $42.18 Now $41.60 −1.38% settles Dec 3
  8. Nov 3, 202613d ago 6-K Neutral 2/10 Entry $40.19 Now $41.60 +3.51% settles Dec 2
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $39.13 Now $41.60 +6.31% settles Nov 23
  10. Oct 26, 202622d ago Court Ruling Neutral 4/10 Entry $38.67 Now $41.60 +7.58% settles Nov 24
Showing 10 of 43

US Market Status

Market Closed · Opens in 6h 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026